High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3 g/m(2) over 3 hours daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9 mg/m(2) on day 7 and 4.5 mg/m(2) on day 14 was not tolerated, but HiDAC followed by...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stone, Richard M., Moser, Barry, Sanford, Ben, Schulman, Philip, Kolitz, Jonathan E., Allen, Steven, Stock, Wendy, Galinsky, Ilene, Vij, Ravi, Marcucci, Guido, Hurd, David, Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3023007/
https://ncbi.nlm.nih.gov/pubmed/20688393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2010.07.017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados